Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

My name is Frank Smithuis, I’m a medical doctor and the director of MOCRU, Myanmar Oxford Clinical Research Unit. We focus mainly on infectious diseases and access to health care in the most remote communities.

The main problem for malaria in Southeast Asia, and therefore also in Myanmar, is falciparum malaria because it is the biggest killer. I estimate very roughly, because there’s not a lot of data available, yearly incidents of 5 to10 millions. However, that has gone down substantially and I don’t know what it is at this moment but I expect it to be maybe 100,000, 200,000 or 300,000 cases a year.

There is of course the problem of resistance: the medicines that are used to treat malaria in this region are gradually not effective any more, and the parasite is becoming more and more resistant. This is particularly a problem in Cambodia, Thailand and Vietnam. Actually in Myanmar artemisinin is still effective, resistance is limited, and the artemisinin combination treatment is still effective. In practice, we focus on treating people early in the community. If you treat people early then they can’t transmit malaria and that is very important.

MOCRU and Medical Action Myanmar, an NGO I am working with, focus on working in the most remote communities. That is where malaria is, and there are no health care activities there. We have trained community health workers, villagers, and we trained them how to used rapid tests for malaria, and then gave them enough treatment. We provide medicines, mosquito nets, tests, but also very importantly we keep on training them. When I studied medicine and I saw my first patient, I didn’t know what to do – I learnt a lot but I didn’t know how to manage a patient, and it was a senior doctor that helped me and guided me along. It’s the same for community health workers: we can train them but at a certain moment they need to see patients together with a senior person. That is what we do: we send a team every month to all of these remote communities, and they see patients together. That programme has been very successful; malaria has decreased on average in the communities that we work with by 70% per year, and that has gone on for 6 to 7 years now.

We have to prove to the world, to the ministry of health, to other players, what works and what doesn’t work, I think that’s very important. I can be convinced of something but if I don’t have proof then it’s very difficult to ask other people to implement the same. That’s why when we do activities we measure the results, we compare it with when we do not do these activities. Then we have something in hand, and with these results we go to the government, we go to the ministry of health and we show the results. That has lead several times to a change to treatment protocol so that’s basically it – we do research and we try to change policy. It is very much related to direct service delivery to the people.

There is not so much malaria anymore, so people say ‘so why focus on malaria?’ well if you want to eliminate it, you have to eliminate the last parasite; that’s actually very difficult. You can see with polio, there is very little polio in the world, but when you drop your activities to contain polio and to eliminate polio, polio will come back. It’s the same with malaria – if we stop now or if we stop in the next few years, malaria will come back, and then it was all for nothing.

Frank Smithuis

Professor Frank Smithuis is the director of MOCRU, our Myanmar Oxford Clinical Research Unit. MOCRU involves a network of 6 clinics and 650 community health workers in remote areas.
Most research questions originate from the day to day health issues in this network. Research interests include the epidemiology and management of malaria, and the management of tuberculosis, HIV and opportunistic infections.

More podcasts related to Malaria

Francis Ndungu: Decoding natural immunity to malaria

Francis Ndungu studies malaria immunity using controlled human infection models to understand protective mechanisms in highly exposed populations. His research supports vaccine development and optimisation, including RTS,S and R21. By reducing malaria burden, especially among children and pregnant women, these tools also have the potential to accelerate economic development in endemic countries.

James Watson: Data driven definitions of severe malaria

James Watson studies severe malaria in African children, focusing on improving diagnostic accuracy. By analysing clinical data, he aims to distinguish malaria-related severe illness from other infections and estimate true mortality more reliably. His work supports faster diagnosis and treatment, ultimately reducing preventable child deaths in low-resource settings.

Philippe Guérin: Enabling data reuse to combat infectious diseases

IDDO is a data platform that facilitates the integration and analysis of individual patient data from diverse studies, uncovering new insights otherwise inaccessible. Through meticulous curation and merging of data, IDDO unearth crucial evidence, such as the impact of malaria treatment on malnourished children, a group usually excluded from trials. This comprehensive approach not only informs better treatment strategies but also identifies gaps in current knowledge, guiding future research directions and potentially transforming healthcare guidelines worldwide.

Marta Maia: Vector control to fight malaria

Malaria is mostly controlled through the use of bed nets and insecticides, but progress has stalled and we need new vector control interventions. Mosquitoes can be affected by endectocides carried in the blood of hosts. Clinical trials will determine whether ivermectin administered to human or cattle can be used to impact malaria transmission.

Isabella Oyier: Malaria and immunity

Understanding mutations in the malaria parasite gives us an insight how it escapes the immune system, as well as the mechanisms of drug resistance. This molecular work also helps find better candidates for malaria vaccines. In the long term, surveillance of markers of resistance informs national drug policy.

Melissa Kapulu: Malaria transmission and human infection studies

The efficacy of vaccine developed in naïve population (UK or US) often drops dramatically when used in endemic populations, where individuals are exposed to the vaccine disease target. The Human Malaria Infection Model looks at naturally acquired immunity and correlates of protection. Furthermore, scientists in affected areas build capacity and knowledge base, and integration of scientific thought and processes.

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.